BioMarin reports five-year Pompe disease data showing durable motor function

BioMarin reported that its combination therapy enabled adults with late-onset Pompe disease to maintain walking distance over five years of continuous treatment. Respiratory function remained relatively stable and no new safety signals emerged, supporting the therapy's long-term efficacy and safety profile.